Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

ASCO 2026

Ramez N. Eskander, MD, on Endometrial Cancer: Pembrolizumab Plus Carboplatin/Paclitaxel

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

Atish Choudhury, MD, PhD, on Can Patients With an Exceptional Response to ARPIs Interrupt ADT?

Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial

Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03

Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care

Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib

Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

Evan T. Hall, MD, on Merkel Cell Carcinoma: Tuvusertib With or Without Avelumab

Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer

Lillian L. Siu, MD, on Liquid KRAS Mutation Screening in Patients With Advanced Pancreatic Cancer

Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial

Jonathan W. Goldman, MD, on RET Fusion–Positive NSCLC: Adjuvant Selpercatinib

Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Julie R. Gralow, MD, FACP, FASCO, on Highlights of the 2026 ASCO Annual Meeting

Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide

Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective

John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial

Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status

Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX

Thomas A. Jandl, MD, PhD, on DLBCL: First-Line Odronextamab Plus Chemotherapy

Richard Cathomas, MD, on MIBC: Perioperative Intravesical Recombinant BCG Combined With Chemoimmunotherapy

Ronald C. Chen, MD, MPH, FASCO, on High-Risk Muscle-Invasive Urothelial Carcinoma: HRQoL With Pembrolizumab vs Observation

Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View

Shailender Bhatia, MD, on Adjuvant Avelumab in Patients With Metastatic Merkel Cell Carcinoma

Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC

Christopher A. Barker, MD, on Locally Advanced Unresectable CSCC: RAMPART Trial

Jana de Boniface, MD, PhD, on Breast Cancer With Sentinel Lymph Node Macrometastases: Can Axillary Dissection Be Omitted?

Julie R. Brahmer, MD, FASCO, on Previously Untreated Advanced Squamous NSCLC: HARMONi-6 Trial

Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial

Krishnan R. Patel, MD, on High-Risk Prostate Cancer: Clinico-Transcriptomic Risk Stratification

Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer

Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174

Jason R. Westin, MD, FASC, on Updated Safety and Efficacy From the SUNMO Trial in LBCL

Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial

Colton Jones, MD, on GLP-1 RAs for the Prevention of HCC in High-Risk Individuals

Bjorn Henning Gronberg, MD, PhD, on Extensive-Stage SCLC: Concurrent TRT and Chemoimmunotherapy

Angimar Uriepero-Palma, MD, on CLL: Impact of SGLT2 Inhibitors on Patients With Diabetes

Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3

Misty Dawn Shields, MD, PhD, on SCLC: Expert Point of View

Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial


AACR 2026

Thi Van Trinh Tran, PhD, on the Histopathology of Lung Cancer in Neversmokers

Jonathan Riess, MD, on Zoldonrasib in Previously Treated Patients With KRAS G12D–Mutant NSCLC

Manale El Kharbili, PhD, on a Novel Strategy to Eliminate MRD in HER2-Mutant NSCLC

Fabrice Barlesi, MD, PhD, on Resectable NSCLC: IPH5201 Plus Durvalumab and Platinum-Based Chemotherapy

Lyudmila A. Bazhenova, MD, on ROS1-Positive NSCLC: Taletrectinib in TKI-Naive Patients

Yuji Shibata, MD, PhD, on HER2-Mutant NSCLC: Mechanisms of Zongertinib Resistance

Melissa Johnson, MD, on Advanced Nonsquamous NSCLC: Second-Line Risvutatug Rezetecan and Adebrelimab


2026 ASCO GU

Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT

Anna Clare Wilkins, PhD, MRCP, MBBChir, on Localized Prostate Cancer: MMAI-Derived Biomarker

Enrique Gallardo, MD, on mCRPC: Enzalutamide With or Without Radium-223

Amar Kishan, MD, on Recurrent Prostate Cancer: Hormone Therapy and Postoperative Radiotherapy

Thomas Powles, MD, PhD, FCRP, on a Novel Antibody-Drug Conjugate in Previously Treated Advanced Urothelial Cancer

Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab

Maha H.A. Hussain, MD, FASCO, FACP, on Metastatic Castration-Resistant Prostate Cancer: BRCAAway Trial in Patients With DNA Repair Defects

Neha Vapiwala, MD, on Highlights in Prostate Cancer From ASCO GU 2026


2026 ASCO GI

Ghassan K. Abou-Alfa, MD, on a Novel First-Line Regimen for Unresectable HCC Under Study

Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes

Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab

Elizabeth Smyth, MD, on FLOT Administration in the MATTERHORN Trial

Elena Elimova, MD, on HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy

Daniela Molena, MD, on Surgical Journey in the MATTERHORN Trial

Dina Ioffe, MD, on Disparities in HCC: Do They Affect Systemic Care?

Matthew Strickland, MD, on Locally Advanced Gastric/GEJ Cancer: Tislelizumab Plus Chemoradiotherapy

Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation

Marcel Verheij, MD, PhD, on Resectable Gastric Cancer: Comparing Three Preoperative Regimens


SABCS 2025

Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer

Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data

Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice

Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence


ASH 2025

Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant

Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant

Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy

Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial

Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Krina Patel, MD, MSc, on Anitocabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Benjamin Diamond, MD, on a Novel Quadruplet for Relapsed/Refractory Multiple Myeloma

Guillermo Garcia-Manero, MD, on MDS: Research Highlights From ASH 2025

Dory Abelman, PhD(c), HBHSc, on Newly Diagnosed Multiple Myeloma: Ultradeep Whole-Genome Sequencing of cfDNA

Aaron Gerds, MD, on Using an AI System to Identify Patients Eligible for a Polycythemia Vera Trial

Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, on Ultra–High-Risk Multiple Myeloma: RADAR Trial in Newly Diagnosed Transplant-Eligible Patients

Alexander Lesokhin, MD: Can Patients With Relapsed/Refractory Multiple Myeloma Successfully Pause or Discontinue Elranatamab?

Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine

Jennifer Woyach, MD, on CLL/SLL: Pirtobrutinib vs Ibrutinib in Treatment-Naive and Relapsed/Refractory Disease

Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus Azacitidine

Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

Nitin Jain, MD, on a Triplet Regimen for Richter Transformation

Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange


JADPRO Live 2025

JADPRO Live 2025: United in Care


ESMO Congress 2025

Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab

Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients


IASLC WCLC 2025

Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC

John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC

Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib

Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib

Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy

David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease

Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases

Patrick Goodley, MBBChir, MRCP: What Is the Optimal Upper Age Limit for Lung Cancer Screening?


SOHO 2025

Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL

Farhad Ravandi, MD, on AML: Highlights of Ongoing Research

Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL

Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML

Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML

Nicholas J. Short, MD: Focus on TP53-Mutated ALL

Bijal Shah, MD, on CAR T-Cell Therapy in ALL

Advertisement

Advertisement




Jun
03
Today In Oncology
Online Patient Resources About AI and Cancer Found Lacking
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in Early Breast Cancer
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo